Li Auto에 대한 매도 수량은 투자자에게 Li Auto의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Li Auto (NASDAQ:LI) 주식, 공매도 수량 보고

Li Auto

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.

Li Auto Inc

100,Dollars,And,100,Yuan,On,A,Us,And,China

Government

News

Regulations

Movers

Tech

BABA

BIDU

KWEB

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

수요일(23일) 미국 증시에 상장된 중국 주식은 트럼프 행정부의 최근 발언 이후 중국이 미국과의 무역 긴장을 완화할 것이라는 낙관론에 힘입어 상승했다.알리바바 그룹 홀딩(NYSE:BABA), PDD 홀딩스(NASDAQ:PDD), 그리고 바이두(NASDAQ:BIDU)는 수요일에도 랠리를 계속했다. 니오(NYSE:NIO), 리 오토(NASDAQ:LI), 그리고 샤오펑(NYSE:XPEV) 등 전기차 회사도 강한 상승세를 보였다.

미국 상장 중국 주식, 트럼프의 관세 인하 및 무역 긴장 완화 시사 후 상승

Usa,And,China,Flags,On,A,Concrete,Wall.,Usa,And

Topics

Media

도널드 트럼프 대통령의 무역 파트너에 대한 관세 전쟁에도 불구하고 중국의 무역 흐름은 4월에 탄력을 받았다. 트럼프의 전자 제품에 대한 관세 감면과 대부분의 국가에 대한 상호관세 부과 중단이 순풍을 불러일으키면서 아시아는 무역 혼란을 덜 겪었다.

알리바바·니오·PDD 등 미국에 상장된 중국 주식, 화요일에 급등한 이유는?

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

Pre-Market Outlook

Markets

Trading Ideas

PATH

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 하락했음을 보여 주었고, 지수는 목요일에 &#34;극단적 공포&#34; 영역에 머물렀다. 목요일(13일)에 미국 증시는 경제 데이터 발표 후 다우존스 지수가 500포인트 이상 하락하며 마감했다.

관세 위협으로 다우 지수 500p 이상 하락: 공포·탐욕 지수는 &#39;극단적 공포&#39; 영역에 머물러

Li Auto Inc. - American Depositary Shares

LifeX 2048 Inflation-Protected Longevity Income ETF

LifeX 2049 Inflation-Protected Longevity Income ETF

LifeX 2050 Inflation-Protected Longevity Income ETF

LifeX 2051 Inflation-Protected Longevity Income ETF

LifeX 2052 Inflation-Protected Longevity Income ETF

LifeX 2053 Inflation-Protected Longevity Income ETF

LifeX 2054 Inflation-Protected Longevity Income ETF

LifeX 2055 Inflation-Protected Longevity Income ETF

LianBio ADS (Sponsored)

LianBio

LifeX 2056 Inflation-Protected Longevity Income ETF

LifeX 2057 Inflation-Protected Longevity Income ETF

LifeX 2058 Inflation-Protected Longevity Income ETF

LifeX 2059 Inflation-Protected Longevity Income ETF

LifeX 2060 Inflation-Protected Longevity Income ETF

LifeX 2061 Inflation-Protected Longevity Income ETF

LifeX 2062 Inflation-Protected Longevity Income ETF

LifeX 2063 Inflation-Protected Longevity Income ETF

LifeX 2064 Inflation-Protected Longevity Income ETF

LifeX 2065 Inflation-Protected Longevity Income ETF

LIBERTY PLUGINS INC by Liberty PlugIns, Inc.

Liberty Resources Acquisition Corp Ordinary Shares - Class A

Liberty Resources Acquisition Corp

Liberty Resources Acquisition Corp Units (1 Ord Class A & 1 War)

Liberty Resources Acquisition Corp Warrants - (31/10/2028)

Livechain Inc

Lichen International Limited - Class A Ordinary Shares

Lichen International Ltd

LICT Corp

LI-CYCLE HOLDINGS CORP by Li-Cycle Holdings Corp.

Li-Cycle Holdings Corp

Limco Del Mar

AEye Inc

Chicago Atlantic BDC, Inc. - Common Stock

Chicago Atlantic BDC Inc

Life360 Inc

Life Corp

LFTD Partners Inc

LIFE TECHNOLOGIES CORP COM

Life Crypto

Li-FT Power Ltd

LIF3 - United States Dollar

LIFENET INSURANCE CO. by Lifenet Insurance Co.

Lifenet Insurance Co

LIFE STEM GENETICS INC by Life Stem Genetics Inc.

Life Stem Genetics Inc

LABRADOR IRON ORE RLTY CP by Labrador Iron Ore Royalty Corp.

Labrador Iron Ore Royalty Corp

LIG Assets Inc

Lightning

Lennox International Inc

LikeCoin

Liberty Latin America Ltd. - Class A Common Stock

Liberty Latin America Ltd

LIBERTY LATIN AMERICA B by Liberty Latin America Ltd.

Liberty Latin America Ltd. - Class C Common Stock

ARGENTINA LITH & ENERGY by Argentina Lithium & Energy Corp

Argentina Lithium & Energy Corp

LILIUM N V SHS CL A

Lilium NV

LILIUM N V WT EXP

Linamar Corp

iMe Lab

SKYCAP INVESTMENT HOLDING by Skycap Investment Holdings Inc.

Skycap Investment Holdings Inc

Themes ETF Trust Themes Lithium & Battery Metal Miners ETF

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma Inc

LIMITLESS X HOLDINGS INC by Limitless X Holdings Inc.

Limitless X Holdings Inc

Linde PLC

Linear Finance

Lincoln Educational Services Corporation - Common Stock

Lincoln Educational Services Corp

Lindblad Expeditions Holdings Inc. - Common Stock

Lindblad Expeditions Holdings Inc

Lineage Inc

LINDIAN RESOURCES LTD by LINDIAN RESOURCES LTD.

Lindian Resources Ltd

Interlink Electronics, Inc. - Common Stock

Interlink Electronics Inc

Chainlink - United States Dollar

LINKDOWN - United States Dollar

Chainlink - TrueUSD

LINKUP - United States Dollar

LINEAR MINERALS CORP by LINEAR MINERALS CORP.

Linear Minerals Corp

LIONTOWN RESOURCES LTD by Liontown Resources Ltd.

Liontown Resources Ltd

LIFE INS CO ALA by Life Insurance Co. Of Alabama

Life Insurance Co

LIFE INS CO ALA A by Life Insurance Co. Of Alabama

LINIU TECHNOLOGY GRP ORD by LiNiu Technology Group

LiNiu Technology Group

Lion Energy Ltd

Lionsgate Studios Corp

Lion Corp

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

LIQUID HOLDINGS GROUP INC by Liquid Holdings Group, Inc.

Liquid Holdings Group Inc

Liquid Meta Capital Holdings Ltd Ordinary Shares

LiqTech International, Inc. - Common Stock

LiqTech International Inc

LITHIUM SOUTH DEV CORP by Lithium South Dev Corp.

Lithium South Development Corp

Li-S Energy Ltd

Global X Lithium & Battery Tech ETF

Litentry - United States Dollar

LightInTheBox Holding Co., Ltd. American Depositary Shares, each representing twelve ordinary shares

LightInTheBox Holding Co Ltd

Lumentum Holdings Inc

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $54 to $45.

Price Target

Analyst Ratings

RCKT

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and lowers the price target from $28 to $25.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 20 years by 8.79% on an annualized basis producing an average annual return of 16.95%. Currently, Domino's Pizza has a market capitalization of $16.40 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 20 years ago, it would be worth $22,913.88 today based on a price of $478.90 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746829811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Domino's Pizza 20 Years Ago Would Be Worth Today

UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $102 to $75.

CCOI

UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $32 to $30.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30

UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Buy and lowers the price target from $154 to $152.

UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $63 to $59.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

UBS analyst John Lovallo maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $74 to $72.

TREX

UBS Maintains Neutral on Trex Co, Lowers Price Target to $72

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

XRAY

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

UBS analyst Kunal Madhukar maintains ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) with a Neutral and lowers the price target from $7 to $6.

UBS Maintains Neutral on ZipRecruiter, Lowers Price Target to $6

UBS analyst Seth Gilbert maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Neutral and lowers the price target from $3.5 to $2.

VERI

UBS Maintains Neutral on Veritone, Lowers Price Target to $2

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral and lowers the price target from $10 to $8.6.

TMCI

UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 12.37%. Currently, UnitedHealth Group has a market capitalization of $344.73 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $3,285.34 today based on a price of $380.02 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746828911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

UBS analyst Kevin Mcveigh maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Neutral and lowers the price target from $2.95 to $1.9.

UBS Maintains Neutral on Rackspace Technology, Lowers Price Target to $1.9

UBS analyst Chris Zhang maintains International Money (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMXI#NASDAQ">IMXI</a>) with a Neutral and lowers the price target from $17 to $12.

IMXI

UBS Maintains Neutral on International Money, Lowers Price Target to $12

UBS analyst Timothy Arcuri maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and raises the price target from $22 to $25.

ALGM

UBS Maintains Buy on Allegro Microsystems, Raises Price Target to $25

UBS analyst Peter Grom maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral and raises the price target from $24 to $25.

Comments

Li Auto

매도 수량

Li Auto (NASDAQ:LI) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌